Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on August 22, 2024. The report addresses a critical regulatory matter regarding the company's continued listing on The Nasdaq Capital Market. Note: The input metadata references "Bio Green Med Solution, Inc.," but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
- Stockholders' Equity (Dec 31, 2023): $607,000
- Stockholders' Equity (June 30, 2024): $999,000
- Recent Capital Raise: Approximately $6.3 million in net proceeds received on May 2, 2024.
- Warrant Exercise: No warrants were exercised during the period ended June 30, 2024, despite prior expectations of up to $4 million in exercises.
- Compliance Threshold: Nasdaq Listing Rule 5550(b)(1) requires stockholders' equity of at least $2.5 million.
Material Changes and Delisting Notice
The company received a notice from Nasdaq on August 22, 2024, confirming non-compliance with the Equity Rule due to stockholders' equity of less than $2.5 million as of June 30, 2024. Although the company raised $6.3 million in May 2024, the equity balance remained below the required threshold. The Nasdaq Staff determined the company failed to evidence the ability to achieve near-term compliance or sustain it over an extended period.
Unless an appeal is filed by August 29, 2024, trading of the company's common and preferred stock will be suspended on September 3, 2024, and the securities will be removed from Nasdaq listing.
Outlook, Management Commentary, and Risks
Management intends to request an appeal of the Staff's determination and submit a hearing request to the Nasdaq Hearings Panel by the August 29, 2024 deadline. Filing this request will stay any delisting action until the hearing process concludes. However, the filing explicitly states there is no assurance that the hearing will be successful or that the company will satisfy continued listing criteria even if the listing is maintained post-hearing.
Investor Verification Checklist
- Verify the status of the appeal request with the Nasdaq Hearings Panel by August 29, 2024.
- Confirm whether the company has executed any new capital raises or warrant exercises since June 30, 2024, to bridge the equity gap.
- Monitor for a Form 25-NSE filing, which would confirm the removal of securities from Nasdaq if the appeal fails.
- Review the company's cash burn rate and liquidity position given the equity shortfall.